CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
借助纳米技术助推 CAR-T 细胞走得更远
英文原题：Jump-starting chimeric antigen receptor-T cells to go the extra mile with nanotechnology.
查看英文原题
Jump-starting chimeric antigen receptor-T cells to go the extra mile with nanotechnology.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
尽管在治疗血液系统恶性肿瘤方面取得了成功，CAR-T 细胞疗法仍面临多重挑战，这些挑战阻碍了进展，尤其是在针对实体瘤方面。纳米工程学的最新进展为克服这些挑战提供了若干途径，包括在体外更高效地编程CAR-T、在体内促进肿瘤微环境（TME）中的免疫应答，以及增强CAR-T 的原位功能。在此，我们总结了近期利用纳米技术直接解决阻碍CAR-T 疗法在多种癌症类型中充分发挥潜力的主要障碍的创新成果。最后，我们对该领域的现状以及纳米技术如何塑造CAR-T 和过继细胞疗法在免疫肿瘤学中的未来进行了评论。
展开英文摘要原文
Despite success in treating hematologic malignancies, chimeric antigen receptor-T cell (CAR-T) therapy still faces multiple challenges that have halted progress, especially against solid tumors. Recent advances in nanoscale engineeirng provide several avenues for overcoming these challenges, including more efficienct programming of CAR-Ts ex vivo, promoting immune responsiveness in the tumor microenvironment (TME) in vivo, and boosting CAR-T function in situ.
Here, we summarize recent innovations that leverage nanotechnology to directly address the major obstacles that impede CAR-T therapy from reaching its full potential across various cancer types.
We conclude with a commentary on the state of the field and how nanotechnology can shape the future of CAR-T and adoptive cell therapy in immuno-oncology.
论文信息
- 作者
- Chada NC、Wilson JT
- 第一作者单位
- Department of Biomedical Engineering, Vanderbilt University, Nashville, TN 37235, USA; Medical Scientist Training Program, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.United States
- 通讯作者单位
- Department of Biomedical Engineering, Vanderbilt University, Nashville, TN 37235, USA; Department of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, TN 37235, USA; Vanderbilt Institute for Infection, Immunology, and Inflammation, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Institute of Chemical Biology, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Center for Immunobiology, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA. Electronic address: john.t.wilson@vanderbilt.edu.United States
- 文献类型
- 综述
- 期刊
- Current opinion in biotechnology2024 Oct
- 原文标识
- PubMed 39168033 · DOI 10.1016/j.copbio.2024.103179